QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.134494v1 325/2/601    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Yuhki, K.-i. Articles by Oh-ishi, S. PubMed PubMed Citation Articles by Yuhki, K.-i. Articles by Oh-ishi, S.

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Prostaglandin I₂ Plays a Key Role in Zymosan-Induced Mouse Pleurisy

Department of Pharmacology, Asahikawa Medical College, Asahikawa, Japan (K.Y., F.U.); Pharmaceutical Research Center, School of Pharmacy, Iwate Medical University, Iwate, Japan (H.N.); DDS Institute, Jikei University School of Medicine, Tokyo, Japan (A.U.); Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan (H.K., F.K.); Department of Pharmacology, Faculty of Medicine (S.N.) and Department of Physiological Chemistry, Faculty of Pharmaceutical Sciences (Y.S.), Kyoto University, Kyoto, Japan; Department of Applied Biochemistry, Tokai University, Kanagawa, Japan (M.M.); and Basic Research Division, Kitasato Institute, Tokyo, Japan (S.O.)

Zymosan, the cell wall of Saccharomyces cerevisiae, induces innate immune responses involving prostanoid production and complement activation. However, the roles of prostanoids in zymosan-induced inflammation and their interaction with the complement system remain to be determined. To clarify these issues, we examined zymosan-induced pleurisy in mice lacking receptors for prostaglandin (PG) E₂ (EP^–/– mice) or PGI₂ (IP^–/– mice). Zymosan-induced exudate formation was significantly reduced in IP^–/– mice compared with wild-type (WT) mice, whereas none of the EP^–/– mice (EP₁^–/–, EP₂^–/–, EP₃^–/–, and EP₁^–/–₄ mice) showed any significant difference from WT mice. Furthermore, indomethacin, an inhibitor of prostanoid biosynthesis, suppressed exudate formation in WT mice to almost the same level as that of IP^–/– mice. Accordingly, significant production of PGI₂ in the pleural cavity, suggested to be cyclooxygenase-2-dependent, was observed after zymosan injection. Complement activation in the pleural cavity after zymosan injection was confirmed, and preinjection of cobra venom factor (CVF), to deplete blood complement C3, was significantly suppressed after zymosan-induced exudate formation in WT mice. Simultaneous treatment with indomethacin and CVF further suppressed exudate formation in WT mice compared with each treatment alone. Because, some degree of exudate formation was still observed, other factor(s) seem to be involved. However, platelet-activating factor, a promising candidate as one such factor, was not involved in zymosan-induced exudate formation. These results clearly indicate that the PGI₂-IP system together with the complement system plays a key role in exudate formation in zymosan-induced pleurisy.

Address correspondence to: Dr. Koh-ichi Yuhki, Department of Pharmacology, Asahikawa Medical College, 2-1-1-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan. E-mail: yukik{at}asahikawa-med.ac.jp